Copy to clipboard 
Evonik has invested in the startup company SYNOSTE and now holds a minority share in the medical device company based in Düsseldorf, Germany and Helsinki, Finland. SYNOSTE, founded in 2012, has developed an implant for minimally invasive treatment of leg length discrepancy that is manufactured with Evonik’s VESTAKEEP® PEEK polymer.
SYNOSTE worked with Orton, a Helsinki-based hospital specializing in orthopedics, to develop the implant that is similar to an intramedullary nail and is fixed to the bone after the bone has been cut. Over the course of several months, the implant is electromagnetically extended in increments of 0.5 millimeters. This causes fresh bone to form between the two halves of the bone. Using this method, it is possible to increase the length of the bone by several centimeters.
SYNOSTE expects to launch the Nitinail™ implant in 2017.
Source: Evonik
